CD34 and non-Hodgkin lymphoma: In a randomized phase II study in patients with NHL or multiple myeloma, plerixafor was well tolerated, and the combination of plerixafor and granulocyte colony-stimulating factor (G-CSF) increased the likelihood of obtaining ≥5 × 106 CD34+ cells/kg in fewer apheresis days compared with G-CSF as a single agent [11].